Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

667
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
667
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

526
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
526
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

164
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
164
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

708
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
708
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

6.1K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.1K
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

7.9K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
7.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fluid de-resuscitation in critical illness: are we measuring the right endpoint?

Panminerva medica·2026
Same author

A case of early pregnancy pulmonary embolism following mifepristone administration: a call for increased pharmacovigilance and research.

Blood transfusion = Trasfusione del sangue·2026
Same author

Xanthogranulomatous Inflammatory Pelvic Mass Mimicking Malignancy: Successful Conservative Treatment and Narrative Insights into Diagnosis and Management.

Journal of clinical medicine·2026
Same author

The Confounder in Plain Sight: A Retrospective Pilot Analysis on the Impact of Comorbidity on C-Reactive Protein Utility for Differentiating Bacterial vs. Viral Infections.

Antibiotics (Basel, Switzerland)·2026
Same author

Catheter-Related Superficial Venous Thrombosis of the Upper Extremity: A Narrative Review of Current Evidence, Diagnostic Pathways, and Management Strategies.

Journal of blood medicine·2026
Same author

From Measuring to Protecting "Days at Home": Toward Frailty-Informed Monitoring After Serious Health Events.

Journal of the American Geriatrics Society·2026

Related Experiment Video

Updated: Jul 9, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.7K

Statins Effects on Blood Clotting: A Review.

Carmine Siniscalchi1, Manuela Basaglia2, Michele Riva2

  • 1Angiology Unit, Department of Internal Medicine, Parma University Hospital, 43121 Parma, Italy.

Cells
|December 9, 2023
PubMed
Summary

Statins, used for cardiovascular disease, show potential anticoagulant and antiplatelet effects. These properties may help reduce venous thromboembolism (VTE) and related deaths, though further research is needed.

Keywords:
factor V/Vafactor XIII/XIIIafibrinfibrinogenprotein C pathwaystatinthrombintissue factortissue factor pathway inhibitorvenous thromboembolism

More Related Videos

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.3K
Hemocompatibility Testing of Blood-Contacting Implants in a Flow Loop Model Mimicking Human Blood Flow
09:41

Hemocompatibility Testing of Blood-Contacting Implants in a Flow Loop Model Mimicking Human Blood Flow

Published on: March 5, 2020

9.2K

Related Experiment Videos

Last Updated: Jul 9, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.7K
Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.3K
Hemocompatibility Testing of Blood-Contacting Implants in a Flow Loop Model Mimicking Human Blood Flow
09:41

Hemocompatibility Testing of Blood-Contacting Implants in a Flow Loop Model Mimicking Human Blood Flow

Published on: March 5, 2020

9.2K

Area of Science:

  • Pharmacology
  • Hematology
  • Cardiovascular Medicine

Background:

  • Statins are widely prescribed lipid-lowering drugs targeting cholesterol biosynthesis.
  • Their role in venous thromboembolism (VTE) prevention and management requires further elucidation.
  • Existing data suggest statins may influence blood clotting and platelet function.

Purpose of the Study:

  • To review biological evidence and experimental data on statins' direct interference with the clotting system.
  • To explore the potential anticoagulant and antiplatelet mechanisms of statins.
  • To assess the implications of these mechanisms for VTE prevention.

Main Methods:

  • Review of experimental studies and clinical data on statin effects on coagulation factors and pathways.
  • Analysis of statin's impact on tissue factor, thrombomodulin, thrombin generation, and fibrinogen cleavage.
  • Examination of evidence for statin-induced antiplatelet effects.

Main Results:

  • Statins demonstrate anticoagulant effects by downregulating tissue factor and enhancing thrombomodulin expression, reducing thrombin generation.
  • They impair fibrinogen cleavage and reduce activation of factors V and XIII.
  • Statins exhibit antiplatelet effects, inhibiting platelet activation, adhesion, and aggregation.

Conclusions:

  • Statin-induced anticoagulant and antiplatelet effects provide a biological basis for their potential role in VTE prevention.
  • These mechanisms may partially explain observed reductions in VTE and associated mortality.
  • While evidence for arterial thrombosis prevention is robust, the role of statins in VTE warrants further investigation.